|
|
|
Volumn 18, Issue 101, 2009, Pages 114-
|
|
Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC ANTIMETABOLITE;
CISPLATIN;
CYTOTOXIN;
DRUG DERIVATIVE;
GLUTAMIC ACID DERIVATIVE;
GUANINE;
PEMETREXED;
THYMIDYLATE SYNTHASE;
ARTICLE;
CLINICAL TRIAL;
DRUG ANTAGONISM;
DRUG APPROVAL;
DRUG COMBINATION;
EUROPE;
HUMAN;
LUNG NON SMALL CELL CANCER;
LUNG TUMOR;
METASTASIS;
ANTIMETABOLITES, ANTINEOPLASTIC;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARCINOMA, NON-SMALL-CELL LUNG;
CISPLATIN;
CLINICAL TRIALS AS TOPIC;
CYTOTOXINS;
DRUG APPROVAL;
DRUG THERAPY, COMBINATION;
EUROPE;
GLUTAMATES;
GUANINE;
HUMANS;
LUNG NEOPLASMS;
NEOPLASM METASTASIS;
THYMIDYLATE SYNTHASE;
|
|
EID: 68949133153
PISSN: 11677422
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (1)
|
|
References (0)
|